Concentration of latanoprost ophthalmic solution after 4 to 6 weeks' use in an eye clinic setting

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 1, 2006, Pages 222-225

  Varma, Rohit ^a   Winarko, Jonathan ^a   Kiat Winarko, Tien ^a   Winarko, Benjamin ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; LATANOPROST; ANTIHYPERTENSIVE AGENT; DRUG; PROSTAGLANDIN F;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG STORAGE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR HYPERTENSION; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ROOM TEMPERATURE; STORAGE TEMPERATURE; TREATMENT DURATION; DRUG STABILITY; GLAUCOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TEMPERATURE; TIME;

AGED; ANTIHYPERTENSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; DRUG STORAGE; FEMALE; GLAUCOMA; HUMANS; MALE; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; PROSTAGLANDINS F, SYNTHETIC; TEMPERATURE; TIME FACTORS;

EID: 33644839528     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-1367     Document Type: Article

References (9)

1. Committee for Proprietary Medicinal Products (CPMP). The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. Note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution. London: European Medicine Agency, 1999.
2. Xalatan Package insert. New York, NY: Pfizer Inc.; 2003.
3. Morgan PV, Proniuk S, Blanchard J, Noecker RJ. Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma. 2001;10:401-405.
4. Weather.com. Monthly Climatology for Travel Section Web site. Available at: http://www.weather.com/outlook/travel/climatology/monthly/USCA0828. Accessed October 25, 2002.
5. Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage and in-life utilization. J Glaucoma. 2001;10:483-486.
6. FDA/CDER guidance documents. Food and Drug Administration Web site. Stability testing for New Drug Applications. Available at: http://www.fda.gov/ cder/guidance/index.htm. Accessed February 8, 2005.
7. Alm A, Villumsen J, Tornquist P, et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure: a one-month study. Ophthalmology. 1993;100:1312-1317.
8. Fristrom B, Nilsson SE. A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension. Br J Ophthalmol. 1997;81:867-870.
9. Diestelhorst M, Krieglstein GK, Lusky M, Nagasubramanian S. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Surv Ophthalmol. 1997;41:S77-S81.